Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intercept Pharmaceuticals (NQ: ICPT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intercept Pharmaceuticals

< Previous 1 2 3 4 5 6 7 Next >
Intercept Shares Fall After Interim Analysis On Late-Stage NASH Study
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) announced positive topline results from a new interim analysis of its ongoing pivotal Phase 3 REGENERATE trial of OCA in patients with liver fibrosis due... 
Via Benzinga
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again
Via Benzinga
Analysts Expect Clarity Imminent On Intercept's NASH Story
Via Benzinga
Analyst Ratings for Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Intercept Shares Are Rising Today
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has 
Via Benzinga
Intercept Pharma Scores $450 Million Deal For Its Flagship Liver Drug
A U.K.-based pharmaceutical company will sell Ocaliva outside the U.S. 
Via Investor's Business Daily
Jim Cramer Prefers This Oil Stock Over Occidental Petroleum
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is a total spec. 
Via Benzinga
Intercept Pharmaceuticals's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, Intercept Pharmaceuticals's (NASDAQ:ICPT) reported sales totaled $88.58 million. Despite a 52.36% increase in earnings, the company posted a loss of... 
Via Benzinga
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster... 
Via FinancialNewsMedia
First Patient Dosed in Phase 2 Study of Intercept's OCA and Bezafibrate Combination for Primary Biliary Cholangitis
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) dosed first patient in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients... 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Intercept Pharmaceuticals: Q1 Earnings Insights
Intercept Pharmaceuticals (NASDAQ:ICPT) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Outlook For Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Drops 650 Points; Silicon Motion Shares Spike Higher
U.S. stocks remained lower toward the end of trading, with the Nasdaq Composite dropping more than 650 points on Thursday. 
Via Benzinga
83 Biggest Movers From Yesterday
Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results. 
Via Benzinga
Earnings Scheduled For May 6, 2022
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Dow Sheds Nearly 1,000 Points as Selloff Deepens
Stocks are sharply lower at midday, in what is shaping up to be another volatile day on Wall Street. 
Via Talk Markets
Mid-Day Market Update: U.S. Stocks Extend Losses; Dow Dips Over 1,100 Points
U.S. stocks extended losses midway through trading, with the Dow Jones dipping more than 1,100 points on Thursday. 
Via Benzinga
Why Is Intercept Pharmaceuticals (ICPT) Stock Up Today?
Intercept Pharmaceuticals (ICPT) stock is soaring higher on Thursday after the biopharmaceutical company revealed a deal with Advanz Pharma. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
57 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Intercept Pharmaceuticals Q1 2022 Earnings Conference Call On May 6, 2022 At 08:30 AM ET
Intercept Pharmaceuticals (NASDAQ:ICPT) will host a conference call at 08:30 AM ET on May 6, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! 
Via InvestorPlace
Looking Into Intercept Pharmaceuticals's Return On Capital Employed
Intercept Pharmaceuticals (NASDAQ:ICPT) brought in sales totaling $92.40 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 898.9%,... 
Via Benzinga
Analyst Ratings For Intercept Pharmaceuticals
Analysts have provided the following ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers IsoPlexis (NASDAQ:ISO) shares moved upwards by 22.8% to $5.5 during Wednesday's pre-market session. The company's market cap stands at $214.2 million. The... 
Via Benzinga
Intercept Pharmaceuticals: Q4 Earnings Insights
Intercept Pharmaceuticals (NASDAQ:ICPT) reported its Q4 earnings results on Wednesday, March 2, 2022 at 07:00 AM. Here's what investors need to know about the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.